我想看免费的a片|人人操屄去人人操|日本免费三级片网站|羞羞资源久久在线|亚洲一二三四区久久久日韩|高清无码精品视频在线观看|日韩一级不卡视频|黄色三级电影片一一区|日本三级片小说在线|日韩成人三级片免费播放

更新于 9月10日

聯(lián)盟管理經(jīng)理(Alliance Manager)

1.2-2.4萬
  • 北京大興區(qū)
  • 經(jīng)驗不限
  • 博士
  • 全職
  • 招1人

雇員點評標(biāo)簽

  • 同事很nice
  • 工作環(huán)境好
  • 團隊執(zhí)行強
  • 氛圍活躍
  • 人際關(guān)系好
  • 管理人性化

職位描述

生物藥醫(yī)藥研發(fā)項目ALLIANCE MANAGER早研項目聯(lián)盟管理
Key Responsibilities:
1.Lead end-to-end alliance management for biopharmaceutical collaboration projects, acting as the primary point of contact both internally and externally to drive projects forward and deliver on objectives.
2.Address partner’s requirements in accordance with the agreement, coordinate cross-functional teams (including R&D, Finance, Legal), track project milestones and risks, and implement practical solutions.
3.Organize and lead Joint Steering Committee (JSC) meetings, facilitate key decision-making and ensure transparent communication, while maintaining alignment with contractual agreements and company strategy.
Qualifications:
1.Advanced degree (M.S. or Ph.D.) in biopharmaceuticals or a related discipline; international work or study experience (e.g., U.S. or European) is a plus.
2.Full professional proficiency in English, with demonstrated ability to conduct business communications and prepare documents in English.
3.Strong understanding of the entire biopharmaceutical development process; hands-on research or project management experience in early R&D, preclinical pharm/tox, or clinical development of large-molecule therapeutics (e.g., antibodies/ADCs) is highly preferred.
4.Excellent communication, coordination, and problem-solving skills, with proven ability to identify and mitigate risks. Must be proactive, results-oriented, and able to thrive in a collaborative environment.
——————
√ Focus: Biopharma alliance management & project leadership
√ Requires: Advanced degree + fluent English + deep industry experience
√ Strongly encourage candidates with global perspective to apply

工作地點

北京大興區(qū)百奧賽圖

職位發(fā)布者

劉女士/招聘

三日內(nèi)活躍
立即溝通
公司Logo百奧賽圖(北京)醫(yī)藥科技股份有限公司公司標(biāo)簽
百奧賽圖(股票代碼:02315.HK)是一家創(chuàng)新技術(shù)驅(qū)動新藥研發(fā)的國際性生物技術(shù)公司,致力于成為全球新藥發(fā)源地?;诘讓踊蚓庉嫾夹g(shù),百奧賽圖自主研發(fā)了RenMice?(RenMab?、RenLite?、RenNano?、RenTCR-mimicTM)平臺,用于全人治療性單克隆抗體、雙/多特異性抗體、雙抗ADC、納米抗體和類TCR抗體的發(fā)現(xiàn)。百奧賽圖正在對1000多個潛在可成藥的靶點進行規(guī)?;幬镩_發(fā)(“千鼠萬抗TM”計劃),并已建立起40多萬條全人抗體序列庫,用于全球合作。截至2023年12月31日,百奧賽圖已簽署了103項藥物合作開發(fā)/授權(quán)/轉(zhuǎn)讓協(xié)議并與包括多家MNC在內(nèi)的企業(yè)達成了47個靶點項目RenMice?平臺授權(quán)開發(fā)合作;多個臨床階段抗體分子也達成了對外授權(quán)合作。公司子品牌BioMice?提供幾千種包括靶點人源化小鼠在內(nèi)的基因編輯動物和細胞模型,同時為全球客戶提供臨床前藥理藥效和基因編輯服務(wù)。百奧賽圖總部位于北京,在中國(江蘇海門、上海)、美國(波士頓、舊金山)及德國海德堡等地設(shè)有分支機構(gòu)。
公司主頁